• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mind Medicine Mindmed Inc (NQ: MNMD )

    5.615 -0.235 (-4.02%)
    Streaming Delayed Price Updated: 2:45 PM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 443,628
    Open 5.820
    Bid (Size) 5.610 (8)
    Ask (Size) 5.620 (2)
    Prev. Close 5.850
    Today's Range 5.560 - 5.940
    52wk Range 2.410 - 12.22
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
    The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
    Via Talk Markets
    Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
    While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
    Via Talk Markets

    Performance

    YTD
    +55.11%
    +55.11%
    1 Month
    -7.34%
    -7.34%
    3 Month
    -20.58%
    -20.58%
    6 Month
    -41.02%
    -41.02%
    1 Year
    +83.50%
    +83.50%

    More News

    Read More
    MindMed Announces New Employee Inducement Grants
    From Mind Medicine Inc.
    Via Business Wire
    Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
    Via Talk Markets
    Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
    Via Benzinga
    Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    MindMed to Participate in September Investor Conferences
    From Mind Medicine Inc.
    Via Business Wire
    Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
    Via Talk Markets
    Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
    Via Talk Markets
    MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024
    Via InvestorPlace
    MindMed Reports Second Quarter 2024 Financial Results and Business Updates
    From Mind Medicine Inc.
    Via Business Wire
    Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
    From Mind Medicine (MindMed) Inc.
    Via Business Wire
    Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
    From Mind Medicine (MindMed) Inc.
    Via Business Wire
    MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
    From Mind Medicine Inc.
    Via Business Wire
    MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
    From Mind Medicine Inc.
    Via Business Wire
    EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
    Via Benzinga
    MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
    From Mind Medicine Inc.
    Via Business Wire
    MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
    From Mind Medicine Inc.
    Via Business Wire
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    Via Talk Markets
    3 Psychedelic Stocks to Ride to the Moon and Beyond
    Via InvestorPlace
    Exposures Product Safety
    FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
    Via InvestorPlace
    Exposures Product Safety
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Via Talk Markets
    MindMed to be Included in Russell 2000® and Russell 3000® Indexes
    From Mind Medicine Inc.
    Via Business Wire
    Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M
    Via Benzinga
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.